Status:
UNKNOWN
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis
Lead Sponsor:
Medical University of Graz
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimumab does not i...
Detailed Description
Patients with moderate to severe psoriasis who have received treatment with adalimumab (loading dose of 80 mg and thereafter 40 mg s.c. biweekly) for at least 6 weeks without a PASI reduction of 75% o...
Eligibility Criteria
Inclusion
- Psoriasis patients with PASI reduction of less than 75% after at least 6 weeks of treatment with adalimumab.
Exclusion
- Pregnancy or lactation
- History of skin cancer
- Presence of or history of malignant skin tumors
- Dysplastic melanocytic nevus syndrome
- Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)
- Autoimmune disorders such as Lupus erythematosus or Dermatomyositis
- Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others
- General poor health status
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00638469
Start Date
March 1 2008
End Date
December 1 2014
Last Update
November 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz, Department of Dermatology
Graz, Austria, A-8036